A Study of YL242 in Subjects With Advanced Solid Tumors (NCT07197827)
A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors.
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
Who can join: Review the eligibility criteria below.
Location: US-201 — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- US-201 — New Haven, Connecticut
- US-202 — Sarasota, Florida
- US-204 — Boston, Massachusetts
- US-206 — Grand Rapids, Michigan
- US-205 — Nashville, Tennessee
- US-203 — Houston, Texas
- US-207 — San Antonio, Texas
- AUS-101 — Liverpool, New South Wales
- AUS-102 — Darlinghurst, Victoria
- AUS-104 — Fitzroy, Victoria
- AUS-103 — Heidelberg, Victoria
- AUS-105 — Nedlands, Western Australia
- CN-303 — Harbin, Heilongjiang
- CN-301 — Shanghai, Shanghai Municipality
- CN-302 — Hangzhou, Zhejiang
📞 Contact the Study Coordinator
Phone: +86 0512-62858368
Email: clinicaltrials@medilinkthera.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.